RABL6 and breast carcinoma: Several studies have reported that RABL6 was highly expressed in many cancers, such as non-small cell lung cancer (NSCLC), breast cancer, and pancreatic ductal adenocarcinoma (PDAC), and is often related to the poor prognosis for the patients (10–12).